Cardiovascular Today—May 7, 2026

LucidQuest

5 hours ago

This week’s Cardiovascular update highlights regulatory actions, clinical progress, AI-enabled imaging, real-world data, and device innovation.

In Today’s Newsletter

Dive deeper

💉 NICE backs semaglutide for cardiovascular prevention [1] [UK • 28 Apr 2026]

https://leicesterbrc.nihr.ac.uk/nice-study/
Context: SELECT enrolled 17,604 people and showed 20% lower serious cardiovascular events versus placebo on background cardiovascular medicines.
Key point: NICE recommended weekly semaglutide (Wegovy, Novo Nordisk) for overweight people with BMI ≥27 at high cardiovascular risk.
Implication: May influence prescriber choice and payer reviews pending full data.

🫀 Abbott gains FDA clearance and CE mark for Ultreon 3.0 [2] [US/EU • 29 Apr 2026]

https://cardiovascularnews.com/abbotts-latest-generation-ultreon-software-gains-fda-approval-ce-mark/
Context: The software offers one-second OCT pullback, AI plaque assessment, PCI planning guidance, and post-stent assessment.
Key point: Abbott received FDA clearance and CE marking for Ultreon 3.0, an AI-powered OCT imaging platform for PCI.
Implication: Signals investment in AI-enabled intravascular imaging and PCI workflow support.

⚖️ Tirzepatide linked to lower risk after PCI and TAVI [3] [Canada • 29 Apr 2026]

https://cardiovascularnews.com/new-data-link-tirzepatide-to-greatly-reduced-cardiovascular-risk-in-high-risk-patients-undergoing-cardiac-procedures/
Context: PCI analysis compared tirzepatide with dulaglutide; TAVI analysis studied adults with obesity undergoing TAVI from 2020–2025.
Key point: Two TriNetX analyses linked tirzepatide (Eli Lilly; GLP-1/GIP) to lower cardiovascular risk after PCI and TAVI.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🔎 Public interest in TAVI rises sharply [4] [Canada • 29 Apr 2026]

https://cardiovascularnews.com/public-interest-in-tavi-balloons-data-show/
Context: Data were presented at SCAI 2026 and CAIC-ACCI Summit in Montreal, alongside reported growth in TAVR use.
Key point: Researchers reported Google search volume for TAVI rose 340% from 2015–2025, while SAVR searches declined 42%.
Implication: May support targeted patient education as minimally invasive valve options gain visibility.

🦠 NACMI links COVID-19 STEMI to higher mortality [5] [Canada • 29 Apr 2026]

https://cardiovascularnews.com/stemi-patients-with-covid-19-were-67-more-likely-to-die-at-one-year-than-those-without-coronavirus-registry-reveals/
Context: The follow-up sub-study included 2,358 STEMI patients across COVID-19-positive, COVID-19-negative, and matched-control groups.
Key point: NACMI registry data showed COVID-19-positive STEMI patients had 67% higher one-year mortality than STEMI patients without COVID-19.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

📡 ASE releases cardiac ultrasound artifact guideline [6] [US • 04 May 2026]

https://www.itnonline.com/content/new-guideline-cardiac-ultrasound-artifacts-released-ase
Context: The guideline covers artifacts across 2D, spectral Doppler, color Doppler, and 3D echocardiography, with real case examples.
Key point: The American Society of Echocardiography released guidance on identifying and mitigating cardiac ultrasound artifacts.
Implication: May support more consistent interpretation and reduce avoidable diagnostic error.

🧬 Cytokinetics aficamten meets Phase 3 goals [7] [US • 05 May 2026]

Source: Link not provided in input (referenced as Investing.com/Reuters).
Context: The trial randomized 516 participants 1:1 to aficamten or placebo and assessed outcomes at Week 36.
Key point: Cytokinetics said aficamten met both primary endpoints in Phase 3 ACACIA-HCM in symptomatic non-obstructive HCM.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ InspireMD cleared to start SwitchGuard pivotal study [8] [US • 01 May 2026]

https://www.investing.com/news/company-news/inspiremd-receives-fda-approval-for-stroke-device-study-93CH-4654357
Context: The study will evaluate SwitchGuard with the CGuard Prime 80 cm stent platform in transcarotid artery revascularization.
Key point: FDA approved InspireMD’s IDE application to begin the CGUARDIANS III pivotal study of SwitchGuard.
Implication: Signals pipeline investment and device-platform expansion in carotid revascularization.

Why it matters

Cardiometabolic drugs are moving deeper into cardiovascular prevention, with semaglutide and tirzepatide appearing across prevention and procedure-adjacent settings.
Interventional cardiology is adding more AI-enabled imaging and device-based tools, including Abbott’s Ultreon 3.0 and InspireMD’s SwitchGuard.
Registry and real-world data are shaping risk discussions, but several findings still need prospective confirmation.
Imaging quality remains a patient-safety issue, and ASE’s artifact guideline targets a practical source of diagnostic error..

🎯 Catch up on the Top Cardiovascular news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

📚 View the full Cardiovascular archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

FAQ

What did NICE recommend for semaglutide (Wegovy)?

NICE recommended weekly semaglutide for overweight people with BMI ≥27 who are at risk of serious cardiovascular events, alongside existing medicines and lifestyle measures [1].

What is Abbott Ultreon 3.0 used for?

Ultreon 3.0 is an AI-powered OCT platform that supports real-time PCI planning, plaque assessment, and post-stent assessment [2].

What did the tirzepatide analyses show after PCI and TAVI?

The PCI analysis linked tirzepatide with lower adverse outcomes versus dulaglutide, and the TAVI analysis linked tirzepatide with lower MACE in patients with obesity. Both were real-world analyses [3].

What did the NACMI registry report for STEMI patients with COVID-19?

The registry reported higher one-year mortality in COVID-19-positive STEMI patients than in STEMI patients without COVID-19 [5].

What is ACACIA-HCM studying for Cytokinetics?

ACACIA-HCM is a Phase 3 study of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy. The pasted source text says both primary endpoints were met [7].

What is InspireMD’s SwitchGuard study?

CGUARDIANS III will evaluate SwitchGuard with InspireMD’s CGuard Prime 80 cm stent platform in transcarotid artery revascularization procedures [8].

Entities / Keywords

Semaglutide, Wegovy, Ozempic, Novo Nordisk, NICE, NIHR, SELECT, STEP, cardiovascular prevention
Abbott, Ultreon 3.0, optical coherence tomography, OCT, PCI, AI imaging
Tirzepatide, Eli Lilly, dulaglutide, GLP-1, GIP, PCI, TAVI, TriNetX, MACE
Transcatheter aortic valve implantation, TAVI, TAVR, SAVR, SCAI 2026, CAIC-ACCI
STEMI, COVID-19, NACMI registry, one-year mortality
American Society of Echocardiography, ASE, cardiac ultrasound artifacts, echocardiography
Cytokinetics, aficamten, ACACIA-HCM, non-obstructive hypertrophic cardiomyopathy, HCM
InspireMD, SwitchGuard, CGUARDIANS III, CGuard Prime, carotid stent, stroke prevention